Does OATS mosaicplasty actually last longer than microfracture?

For most patients weighing up these two techniques, the core question is straightforward: if I have OATS mosaicplasty instead of microfracture, will the result actually last longer? On the balance of published evidence, the answer is yes — but with important conditions attached.

At five to ten years of follow-up, OATS mosaicplasty consistently produces better results than microfracture on validated functional outcome measures and return-to-sport rates. A large systematic review by Campbell et al. — pooling data from 1,117 patients at a mean 3.6-year follow-up — found that osteochondral autograft transfer produced significantly higher return-to-sport rates than alternative cartilage repair techniques. Pareek et al.'s 2016 ten-year systematic review added that IKDC and Lysholm scores remained significantly improved a decade post-operatively. The 2021 Cartilage Injury of the Knee textbook documents explicitly that microfracture outcomes tend to deteriorate over time — a pattern not seen to the same degree with OATS.

The advantage is not blanket. At shorter follow-up windows — under two to three years — the functional gap between the techniques can be narrow or absent. And OATS is only appropriate for smaller, focal defects in the right patient profile. Durability, in short, comes with eligibility criteria.

Why the tissue type determines how long the repair lasts

The biological reason sits at the heart of the durability gap: the two procedures grow — or transplant — fundamentally different materials.

When microfracture perforates the subchondral bone, blood and marrow-derived stem cells flood the defect and clot. That clot matures into fibrocartilage — a tissue that can fill a gap and reduce symptoms, but which is mechanically closer to scar tissue than to the native joint surface. Fibrocartilage is less stiff, distributes load less evenly across the joint, and wears down more quickly under repeated impact. Think of it as a temporary filler in a pothole: it restores the surface profile but lacks the structural integrity of the original material. Over time, the patch degrades under traffic.

The subchondral bone layer — the dense bone directly beneath the cartilage — compounds this problem. Chen et al. (2011, American Journal of Sports Medicine) showed that the quality of subchondral bone repair after marrow stimulation is directly coupled to how well the overlying cartilage resurfaces in the long term. Poor bone healing undermines the cartilage above it, helping explain the progressive functional decline seen in microfracture cohorts.

OATS takes a different approach entirely. Rather than stimulating new tissue, it transfers cylindrical plugs of intact hyaline cartilage together with their underlying bone from a low-load region of the same knee to the defect. Hyaline cartilage — the original joint-surface material — offers superior stiffness and load distribution. Crucially, the transferred plug also restores the subchondral bone platform, giving the repair a structurally sound foundation from the outset.

What ten-year clinical data shows

Three bodies of evidence map out what happens to these repairs over time — and the picture sharpens considerably once follow-up extends beyond a few years.

The clearest long-term dataset comes from Pareek et al.'s 2016 systematic review of osteochondral autograft transfer outcomes at a ten-year horizon. Two validated knee function scores — the IKDC (International Knee Documentation Committee score) and the Lysholm score, both measuring pain, stability, and everyday functional limitation — showed significant and sustained improvement at the ten-year mark. The Tegner activity score tells a more nuanced story: it quantifies sporting activity level specifically, and here the improvement did not reach statistical significance. That gap is worth naming honestly: OAT appears more reliable at restoring functional comfort than at guaranteeing a full return to pre-injury competitive sporting level, particularly for high-demand athletes.

Campbell et al.'s systematic review — 1,117 patients at a mean follow-up of 3.6 years — adds a practical dimension: OAT produced significantly higher return-to-sport rates than comparator techniques across the pooled data, making this a concrete functional advantage for active patients rather than a marginal statistical one.

The Gudas et al. prospective RCT supplies the most directly comparable evidence, as one of the few head-to-head trials placing mosaicplasty against microfracture in an athletic population. The study found outcomes favouring the autograft group, and it has been cited consistently as a key durability anchor in the cartilage repair literature.

The contrast with microfracture sharpens the further out the data reach. Repeated outcome series show microfracture results declining over time — a deterioration pattern not mirrored in OAT cohorts. That divergence is a central reason the technique is no longer considered a first-line option in most modern cartilage repair algorithms.

Why short-term results can look similar between techniques

Some published studies do report broadly similar functional scores across microfracture, ACI, and OAT — and it is worth understanding why, rather than letting the finding muddy the comparison.

Lim et al., a level 2 comparative study, found no statistically significant difference in Lysholm or Tegner scores between the three techniques. That is a legitimate finding — and at shorter or intermediate follow-up windows, the functional gap between OATS and microfracture can be genuinely narrow. Fibrocartilage does fill the defect, reduces pain, and initially restores a degree of function. Patients in the early post-operative period may have little reason to suspect their repair is performing differently.

The critical variable is when the assessment is made. Microfracture outcomes tend to deteriorate over time, and the divergence from OAT results becomes most apparent beyond two to three years. A one-year Lysholm score does not predict a seven-year result for fibrocartilage repair. Short-term equivalence followed by progressive decline is precisely what makes microfracture the more precarious long-term choice — not a reason to treat the techniques as interchangeable.

Patients reviewing the literature should also note that level I RCT data comparing OATS and microfracture head-to-head in matched knee populations remain scarce. Most high-quality comparative evidence pools mosaicplasty with other osteochondral techniques, which is a genuine limitation of the current evidence base — one that warrants transparency rather than concealment.

Candidate selection, defect size limits, and procedural trade-offs

Deciding whether OATS mosaicplasty is the right procedure depends heavily on defect geometry — and that conversation starts with size.

A single osteochondral plug covers approximately 1–2 cm². When multiple plugs are arranged in a mosaic pattern, coverage extends to roughly 4 cm², but each additional cylinder harvested from the low-load donor zone at the knee's periphery increases the risk of pain or functional change at that harvest site. This donor-site morbidity is a meaningful consideration — not a rare complication — and patients should expect a candid discussion about it at consultation. For defects that exceed what mosaicplasty can reliably cover, techniques such as osteochondral allograft transfer (OCA) or matrix-induced ACI (MACI) become the more appropriate routes, as they are not constrained by how much autograft the patient's own knee can supply.

Microfracture, meanwhile, is not interchangeable with OATS across all defect types. It is not typically recommended for deep osteochondral lesions — situations where the subchondral bone layer also needs restoration — because perforating already-compromised bone without replacing it does not address the underlying structural deficit. OATS restores both the cartilage surface and the bony platform beneath it, which is why it is better matched to those deeper presentations.

For active patients, the recovery timeline difference is clinically significant. Return to previous sport takes meaningfully longer after mosaicplasty than after microfracture, reflecting the more demanding rehabilitation following plug harvest and implantation. Published evidence identifies age under 25 and lesion size under 2 cm² as positive prognostic factors for returning to the same level of sport after osteochondral autograft procedures.

One practical advantage OATS does carry over cell-based alternatives: it is a single-stage operation. There is no separate biopsy appointment, no cell-culture waiting period, and no second surgery — a relevant consideration for patients who cannot accommodate the extended two-stage timeline required by ACI or MACI.

What the evidence gaps mean for your decision

Several of the questions that matter most to an individual decision remain genuinely open in the published literature. The level I head-to-head trial data that would ideally isolate OATS durability against microfracture in matched knee populations does not yet exist for this comparison. Most high-quality comparative evidence pools mosaicplasty with other osteochondral repair techniques rather than isolating the two procedures in matched cohorts, and the precise defect-size boundary at which OATS's durability advantage becomes clinically decisive over microfracture remains undefined by RCT-level data. Donor-site morbidity and patient-reported outcomes at horizons beyond ten years are also incompletely characterised.

What the available evidence does support is a decision framework. Age, activity level, lesion grade, subchondral bone status, and whether prior marrow-stimulation procedures have already been attempted each alter the balance between techniques in ways that no population-level study can resolve for any one knee. Population averages are a useful starting point; they are not a prediction for a specific defect, in a specific patient, with a specific rehabilitation window.

Translating that framework into a specific recommendation requires a consultant assessment that can weigh defect geometry, bone integrity, realistic return-to-sport expectations, and the individual's tolerance for donor-site risk together. The MSK Doctors team assesses cartilage repair candidates without referral or NHS waiting-list delays; anyone wanting to explore whether mosaicplasty or an alternative repair pathway fits their situation can book a consultant appointment directly at mskdoctors.com.

1. [1] Microfracture surgery – Wikipedia. https://en.wikipedia.org/?curid=8840994 https://en.wikipedia.org/?curid=8840994